Trade Abbvie - ABBV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.17 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 202.43 |
| Open | 203.24 |
| 1-Year Change | 12.74% |
| Day's Range | 201.78 - 204.62 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 27, 2025 | 202.43 | 0.84 | 0.42% | 201.59 | 203.53 | 200.45 |
| Mar 26, 2025 | 201.14 | -0.67 | -0.33% | 201.81 | 202.88 | 196.16 |
| Mar 25, 2025 | 201.22 | -7.88 | -3.77% | 209.10 | 209.12 | 199.32 |
| Mar 24, 2025 | 208.95 | -0.03 | -0.01% | 208.98 | 210.90 | 207.46 |
| Mar 21, 2025 | 209.77 | -1.42 | -0.67% | 211.19 | 212.67 | 208.60 |
| Mar 20, 2025 | 211.74 | -0.02 | -0.01% | 211.76 | 213.28 | 211.02 |
| Mar 19, 2025 | 211.98 | -1.44 | -0.67% | 213.42 | 213.69 | 210.45 |
| Mar 18, 2025 | 213.72 | -0.42 | -0.20% | 214.14 | 215.06 | 211.97 |
| Mar 17, 2025 | 214.32 | 2.15 | 1.01% | 212.17 | 215.37 | 208.74 |
| Mar 14, 2025 | 211.53 | 1.90 | 0.91% | 209.63 | 212.74 | 208.21 |
| Mar 13, 2025 | 211.43 | 0.12 | 0.06% | 211.31 | 213.68 | 210.15 |
| Mar 12, 2025 | 211.78 | -0.32 | -0.15% | 212.10 | 213.79 | 208.59 |
| Mar 11, 2025 | 213.36 | -2.09 | -0.97% | 215.45 | 216.24 | 212.35 |
| Mar 10, 2025 | 216.51 | 7.19 | 3.43% | 209.32 | 218.53 | 208.40 |
| Mar 7, 2025 | 213.98 | 3.18 | 1.51% | 210.80 | 214.87 | 208.42 |
| Mar 6, 2025 | 210.51 | 0.52 | 0.25% | 209.99 | 211.51 | 208.18 |
| Mar 5, 2025 | 211.30 | 4.97 | 2.41% | 206.33 | 212.05 | 206.15 |
| Mar 4, 2025 | 209.54 | -4.88 | -2.28% | 214.42 | 215.31 | 208.51 |
| Mar 3, 2025 | 211.31 | 1.87 | 0.89% | 209.44 | 212.22 | 207.76 |
| Feb 28, 2025 | 208.82 | 4.30 | 2.10% | 204.52 | 209.34 | 203.54 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
AbbVie Company profile
AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually.
Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.
The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.
The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers.
Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion.
Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.
| Industry: | Pharmaceuticals (NEC) |
1 N Waukegan Rd
NORTH CHICAGO
ILLINOIS 60064
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com